Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases

The management of castration-resistant prostate cancer (CRPC) presents a clinical challenge because of limitations in efficacy of current therapies. Novel therapeutic strategies for the treatment of CRPC are needed. Antagonists of hypothalamic growth hormone-releasing hormone (GHRH) inhibit growth o...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Rick, Ferenc G., Schally, Andrew V., Szalontay, Luca, Block, Norman L., Szepeshazi, Karoly, Nadji, Mehrdad, Zarandi, Marta, Hohla, Florian, Buchholz, Stefan, Seitz, Stephan
פורמט: Artigo
שפה:Inglês
יצא לאור: National Academy of Sciences 2012
נושאים:
Biological Sciences
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3277159/
https://ncbi.nlm.nih.gov/pubmed/22307626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1120588109
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים